Infectious risk of plasma donations: relationship to safety of intravenous immune globulins

Although intravenous immune globulin (IVIG) preparations may be derived from tens of thousands of donations, the residual risk of viral contamination of recovered plasma appears remarkably low, at least for human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Consequently, most pools are unlikely to contain these viruses although the situation is not as well understoof for US‐derived source plasma. In addition, routine preparation methods are likely to eliminate infectivity from the relatively fragile HIV. Current plasma screening measures arc generally designed to maintain reasonable titres of anti‐HBs in pools, perhaps contributing to the absence of HBV infection. The situation with respect to hepatitis C virus (HCV) is not well understood and it appears that sensitive screening for anti‐HCV may have had an impact on the safety of at least one IVIG preparation. The implementation of effective viral inactivation procedures is expected to eliminate any further risk of HCV infection from IVIG preparations.

[1]  P. Yap,et al.  The viral safety of intravenous immune globulin , 1996, Clinical and experimental immunology.

[2]  M. Björkholm,et al.  Frequent patient-to-patient transmission of hepatitis C virus in a haematology ward , 1995, The Lancet.

[3]  G. Satten,et al.  Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors , 1995, Transfusion.

[4]  G. Satten,et al.  Duration of time from onset of human immunodeficiency virus type 1 infectiousness to development of detectable antibody , 1994, Transfusion.

[5]  P. Snoy,et al.  The effect on the safety of intravenous immunoglobulin of testing plasma for antibody to hepatitis C , 1994, Transfusion.

[6]  Outbreak of hepatitis C associated with intravenous immunoglobulin administration--United States, October 1993-June 1994. , 1994, MMWR. Morbidity and mortality weekly report.

[7]  J. McCullough The nation's changing blood supply system. , 1993, JAMA.

[8]  M. A. Lamb,et al.  Viral safety of clotting factor concentrates. , 1993, Seminars in thrombosis and hemostasis.

[9]  H. Suomela Inactivation of viruses in blood and plasma products. , 1993, Transfusion medicine reviews.

[10]  M. Busch,et al.  Increased detection of hepatitis C virus (HCV)‐infected blood donors by a multiple‐antigen HCV enzyme immunoassay , 1992, Transfusion.

[11]  S. Yei,et al.  Partitioning of hepatitis C virus during Cohn‐Oncley fractionation of plasma , 1992, Transfusion.

[12]  A. Muñoz,et al.  Transmission of Retroviruses from Seronegative Donors by Transfusion during Cardiac Surgery , 1992, Annals of Internal Medicine.

[13]  R. Dodd The risk of transfusion-transmitted infection. , 1992, The New England journal of medicine.

[14]  J. Sninsky,et al.  Evaluation of screened blood donations for human immunodeficiency virus type 1 infection by culture and DNA amplification of pooled cells. , 1991, The New England journal of medicine.

[15]  G. Macchi,et al.  Combination ultrafiltration and 6 M urea treatment of human growth hormone effectively minimizes risk from potential Creutzfeldt-Jakob disease virus contamination. , 1991, Hormone research.

[16]  S. Kleinman,et al.  Risk of human immunodeficiency virus (HIV) transmission by anti‐HIV negative blood , 1988, Transfusion.

[17]  P. Holland Why a new standard to prevent Creutzfeldt‐Jakob disease , 1988, Transfusion.

[18]  J. Ward,et al.  Transmission of human immunodeficiency virus (HIV) by blood transfusions screened as negative for HIV antibody. , 1988, The New England journal of medicine.

[19]  D. Kingsbury,et al.  Chemical disinfection of Creutzfeldt-Jakob disease virus. , 1982, The New England journal of medicine.